George Budwell

George Budwell


George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.

Recent articles

2 Ultra-High-Growth Stocks to Buy Now

Axsome Therapeutics and PhaseBio Pharmaceuticals are soaring this year, but the best could be yet to come for each of these red-hot biotech stocks.

2 Best Biotech Buyout Plays

Atara Biotherapeutics and Crispr Therapeutics stand out as strong takeover candidates. Here's why.

Is Amarin a Buy?

Amarin's stock is stuck in a rut, but this quiet period might turn out to be a great buying opportunity.

Is TG Therapeutics a Buy?

The stock price of this clinical-stage biotech has nearly doubled so far in 2019.

3 Top Healthcare Stocks to Buy in April

GW Pharmaceuticals, Illumina, and Intercept Pharmaceuticals could all be great buys this month.